The United Arab Emirates has approved the Itvisma gene therapy for spinal muscular atrophy (SMA), making it only the second country globally to authorize this advanced treatment. The therapy is approved for patients aged two and older.
Spinal muscular atrophy is a rare genetic disorder that affects muscle strength and movement. Itvisma therapy works by targeting the underlying genetic cause, offering patients improved motor function and the potential to slow disease progression.
Health officials say the approval reflects the UAE’s commitment to adopting innovative treatments and expanding access to advanced healthcare solutions. Patients with SMA now have access to one of the most cutting-edge therapies available worldwide.
The UAE’s regulatory process involved rigorous evaluation of safety, efficacy, and clinical trial data. Experts emphasized that Itvisma met international standards, ensuring that patients receive a therapy backed by robust scientific evidence.
Approval of the therapy also positions the UAE as a regional leader in medical innovation. By adopting next-generation treatments, the country aims to improve patient outcomes and strengthen its healthcare system.
Specialists highlight that early intervention with gene therapy can be life-changing for SMA patients. Children and adults receiving treatment may experience enhanced muscle function, greater mobility, and improved quality of life.
The decision follows global trends in precision medicine, where therapies are tailored to genetic conditions. The UAE’s approval demonstrates a proactive approach to providing patients with access to transformative medical technologies.
Healthcare providers in the UAE are preparing to deliver Itvisma therapy in specialized treatment centers. Training programs and patient support initiatives are being established to ensure safe administration and effective follow-up care.
Patient advocacy groups have welcomed the approval. Families affected by SMA now have access to a treatment that was previously unavailable in the region, offering hope and new opportunities for managing the condition.
Medical experts say that gene therapy approvals like this one could encourage further research and investment in rare disease treatments. Expanding access benefits not only patients but also supports the growth of the country’s biotech and healthcare sectors.
The UAE joins a very select group of countries offering this therapy, reinforcing its position as a hub for advanced medical care. Regulators continue to monitor outcomes and safety data to ensure ongoing compliance with international standards.
The government emphasizes that approvals like Itvisma align with broader healthcare goals, including personalized medicine, patient-centered care, and access to innovative therapies for rare conditions.
By being among the first countries to approve Itvisma, the UAE is paving the way for regional access to cutting-edge treatments. Experts say this could inspire other nations to adopt similar regulatory frameworks for innovative therapies.
Families and clinicians alike have expressed optimism about the potential impact. Gene therapy represents a new frontier in medicine, offering solutions for conditions that previously had limited treatment options.
Overall, the UAE’s approval of Itvisma gene therapy marks a significant milestone in healthcare. Patients with spinal muscular atrophy now have access to a revolutionary treatment, positioning the UAE at the forefront of medical innovation and patient care.
